arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2005-11-3-160-163arthyper-1014Research ArticleОБЗОРЫREVIEWSАнтигипертензивная терапия в профилактике и коррекции когнитивных расстройствAntihypertensive therapy in the prevention and correction of cognitive disordersКонрадиА. О.KonradiA. O.konradi@almazovcentre.ruФГУ НИИ кардиологии Федерального агентства по здравоохранению РФ; ФГБУ «Федеральный медицинский исследовательский центр имени В.А. Алмазова» Минздрава РоссииРоссия200528062005113160163Copyright © Конради А.О., 20052005Конради А.О.Konradi A.O.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1014ReferencesKokmen E. et al. Epidemiology of dementia in Rochester, Minnesota. Mayo Clin Proc 1996; 71: 275-82.Kokmen E. et al. Epidemiology of dementia in Rochester, Minnesota. Mayo Clin Proc 1996; 71: 275-82.Jorm A.F., Korten A.E., Henderson A.S. The prevalence of dementia: a quantitative Integration of the literature. Acta Psychiatr Scand 1987; 76: 465-79.Jorm A.F., Korten A.E., Henderson A.S. The prevalence of dementia: a quantitative Integration of the literature. Acta Psychiatr Scand 1987; 76: 465-79.Fleming К.С. et al. Dementia: Diagnosis end evaluation. Mayo Clin Proc 1995; 70: 1093-107.Fleming К.С. et al. Dementia: Diagnosis end evaluation. Mayo Clin Proc 1995; 70: 1093-107.Roman G. Vascular dementia: Distinguishing characteristics, treatment, and prevention. JAGS 2003; 51: S296-304.Roman G. Vascular dementia: Distinguishing characteristics, treatment, and prevention. JAGS 2003; 51: S296-304.Hachinski V.C., Bowler J.V. Vascular dementia. Neurology 1993; 43: 2159-60.Hachinski V.C., Bowler J.V. Vascular dementia. Neurology 1993; 43: 2159-60.Hagnell O., Franck A., Grasbeck A. et al. Vascular dementia in the Lundby study: 1. A prospective, epidemiological study of incidence and risk from 1957-1972. Neuropsychobiology 1992; 26: 43-9.Hagnell O., Franck A., Grasbeck A. et al. Vascular dementia in the Lundby study: 1. A prospective, epidemiological study of incidence and risk from 1957-1972. Neuropsychobiology 1992; 26: 43-9.Nyenhuis D.L., Gorelick P.B. Vascular dementia: A contemporary review of epidemiology, diagnosis, prevention and treatment. J Am Geriatr Soc 1998; 46: 1437-48.Nyenhuis D.L., Gorelick P.B. Vascular dementia: A contemporary review of epidemiology, diagnosis, prevention and treatment. J Am Geriatr Soc 1998; 46: 1437-48.Selkoe D.J. Alzheimer's disease: Genotypes, phenotype, and treatments. Science 1997; 275: 6З0-1.Selkoe D.J. Alzheimer's disease: Genotypes, phenotype, and treatments. Science 1997; 275: 6З0-1.Hofman A. et al. Atherosclerosis, apolipoprotein E and prevalent of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-4.Hofman A. et al. Atherosclerosis, apolipoprotein E and prevalent of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-4.Stern Y. et al. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994; 271: 1004-10.Stern Y. et al. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994; 271: 1004-10.Roses A.D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996; 47: 387-400.Roses A.D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996; 47: 387-400.Henderson V.W. et al. Estrogen replacement therapy in older women: Comparisons between Alzheimer's disease cases and non-demented control subjects. Arch Neurol 1994; 51: 896-900.Henderson V.W. et al. Estrogen replacement therapy in older women: Comparisons between Alzheimer's disease cases and non-demented control subjects. Arch Neurol 1994; 51: 896-900.Tang M-X et al. Effect of estrogen during menopause on risk' and age at ouset of Alzheimer's disease. Lancet 1996; 348: 429-32.Tang M-X et al. Effect of estrogen during menopause on risk' and age at ouset of Alzheimer's disease. Lancet 1996; 348: 429-32.Birge S.J. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? J Am Geriatr Soc 1996; 44: 865-70.Birge S.J. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? J Am Geriatr Soc 1996; 44: 865-70.McGeer P.L. et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47; 425-32.McGeer P.L. et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47; 425-32.Skoog I. et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.Skoog I. et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.Lande M.B., Kaezorwski J.M., Auinger P. et al. Iterated blood pressure and decreased cognitive Junction among school-age children and adolescents in the United States. J Pediatr 2003; 143: 699-700.Lande M.B., Kaezorwski J.M., Auinger P. et al. Iterated blood pressure and decreased cognitive Junction among school-age children and adolescents in the United States. J Pediatr 2003; 143: 699-700.DeCarli The role of cerebrovascular disease in dementia. Neurologist 2003; 9: 123-36.DeCarli The role of cerebrovascular disease in dementia. Neurologist 2003; 9: 123-36.World Health Organization. The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research. Geneva: World Health Organization, 1993.World Health Organization. The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research. Geneva: World Health Organization, 1993.Forette F. et al. Prevention of dementia in randomised double-bund placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet. 1998; 352: 1347-51.Forette F. et al. Prevention of dementia in randomised double-bund placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet. 1998; 352: 1347-51.Morich F.J., Bieber F., Lewis J.M. et al. Nimodipine in the treatment of probable Alzhemier's disease: results from tiro randomized trials. Clin Drug Invest 1996; 11: 185-95.Morich F.J., Bieber F., Lewis J.M. et al. Nimodipine in the treatment of probable Alzhemier's disease: results from tiro randomized trials. Clin Drug Invest 1996; 11: 185-95.Murray M.D., Lane K.A., Gao S. et al. Preservation of cognitive function with antihypertensive medication, a longitudinal analysis of community-based sample of African. Arch Intern Med 2002; 162: 2090-6.Murray M.D., Lane K.A., Gao S. et al. Preservation of cognitive function with antihypertensive medication, a longitudinal analysis of community-based sample of African. Arch Intern Med 2002; 162: 2090-6.Lever A.F., Brennan P.J. MRC trial of treatment in elderly hypertensives. Clin Exp Hypeitens 1993; 15: 941-2.Lever A.F., Brennan P.J. MRC trial of treatment in elderly hypertensives. Clin Exp Hypeitens 1993; 15: 941-2.Heart Outcomes Prevention Evaluation (HOPE) study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE sub-study. Lancet 2000; 355: 235-59.Heart Outcomes Prevention Evaluation (HOPE) study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE sub-study. Lancet 2000; 355: 235-59.PROGESS Collaborative Study Group. Randomised trial period of perindopril based blood pressure loitering regimen among 6108 individuals with previous stroke or transient aschaemic attack. Lancet 2001; 358. 1033-41.PROGESS Collaborative Study Group. Randomised trial period of perindopril based blood pressure loitering regimen among 6108 individuals with previous stroke or transient aschaemic attack. Lancet 2001; 358. 1033-41.Fournier A., Messerly F., Archad J. et al. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent clinical trials. J Am Coll Cardiol 2004; 43: 1343-7.Fournier A., Messerly F., Archad J. et al. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent clinical trials. J Am Coll Cardiol 2004; 43: 1343-7.Lindholm L.H., Ibsen T., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End-point Reduction in hypertension study (LIFE). Lancet 2002; 359: 1004-10.Lindholm L.H., Ibsen T., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End-point Reduction in hypertension study (LIFE). Lancet 2002; 359: 1004-10.Tadesco M.A., Ratti G., Menella G. et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens,. 1999; 12: 1130-4.Tadesco M.A., Ratti G., Menella G. et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens,. 1999; 12: 1130-4.Lithel H., Hansson L., Skoog I. et al. The study of cognition and prognosis in the elderly (SCOPE). J Hypertension 2003; 21: 875-86.Lithel H., Hansson L., Skoog I. et al. The study of cognition and prognosis in the elderly (SCOPE). J Hypertension 2003; 21: 875-86.Folstein M.F. et al. "Mini-Mental State". A practical method for grading the cognitive slate of patients for the clinician. J Psychiat Res 1975; 12: 189-98.Folstein M.F. et al. "Mini-Mental State". A practical method for grading the cognitive slate of patients for the clinician. J Psychiat Res 1975; 12: 189-98.Schrander J., Luders S., Kulschewski A. et al. Morbidity and mortality after Stroke, eprosaran compared with netrendidpine for secondary prevention (MOSES study). Stroke 2005: 36: 1218-26.Schrander J., Luders S., Kulschewski A. et al. Morbidity and mortality after Stroke, eprosaran compared with netrendidpine for secondary prevention (MOSES study). Stroke 2005: 36: 1218-26.
The authors declare that there are no conflicts of interest present.